Inovio Pharmaceuticals Inc
GBM
Company Profile
Business description
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Contact
660 West Germantown Pike
Suite 110
Plymouth MeetingPA19462
USAT: +1 267 440-4200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
134
Stocks News & Analysis
stocks
Coinbase Earnings: Weak Cryptocurrency Prices Lead to Lower Trading Volume and Net Losses - Clone
We’ve lowered our fair value estimate of Coinbase stock.
stocks
Higher dividend for ASX member of our income pick list
Management lifted guidance and full-year dividend.
stocks
We expect sales growth to moderate for overvalued ASX share
Shares rallied after results but we see future headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,182.50 | 22.30 | -0.24% |
| CAC 40 | 8,326.07 | 9.57 | 0.12% |
| DAX 40 | 24,841.03 | 40.12 | 0.16% |
| Dow JONES (US) | 49,497.29 | 45.31 | 0.09% |
| FTSE 100 | 10,516.03 | 42.34 | 0.40% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,546.67 | 50.48 | -0.22% |
| Nikkei 225 | 56,566.49 | 239.92 | -0.42% |
| NZX 50 Index | 13,031.62 | 86.29 | -0.66% |
| S&P 500 | 6,840.79 | 8.03 | 0.12% |
| S&P/ASX 200 | 8,958.90 | 20.40 | -0.23% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |